0001209191-16-094212.txt : 20160129 0001209191-16-094212.hdr.sgml : 20160129 20160129171317 ACCESSION NUMBER: 0001209191-16-094212 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160127 FILED AS OF DATE: 20160129 DATE AS OF CHANGE: 20160129 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PORTOLA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001269021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 270 EAST GRAND AVENUE, SUITE 22 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-244-6864 MAIL ADDRESS: STREET 1: 270 EAST GRAND AVENUE, SUITE 22 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dier Mardi CENTRAL INDEX KEY: 0001574591 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35935 FILM NUMBER: 161374414 MAIL ADDRESS: STREET 1: PORTOLA PHARMACEUTICALS, INC. STREET 2: 270 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-01-27 0 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001574591 Dier Mardi C/O PORTOLA PHARMACEUTICALS, INC. 270 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Executive VP and CFO Common Stock 2016-01-27 4 A 0 13750 0.00 A 13750 D Stock Option (Right to Buy) 33.49 2016-01-27 4 A 0 55000 0.00 A 2016-01-27 Common Stock 55000 55000 D Performance Stock Unit 2016-01-27 4 A 0 13750 0.00 A 2020-01-27 Common Stock 13750 13750 D Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2016, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. The option shares shall vest as follows: 1/48th of the shares subject to such option shall vest each month after January 1, 2016, subject to Reporting Person's Continuous Service as of each such date. Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follow: 50% of the PSUs will become vested upon achievement of the Issuer's gross product sales target for Andexanet alfa, and up to 50% of the remaining PSUs may vest subject to the timing of approval of Betrixaban by the United States Food and Drug Administration. /s/ Mike Ouimette, as attorney-in-fact 2016-01-27